~~<i id='5B2B206553'><strike id='5B2B206553'><tt id='5B2B206553'><pre id='5B2B206553'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：entertainment 2025-10-06 15:19:31 Page View：3592

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead
Next article： Apple is now the first public company to be valued at $3 trillion

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Liquid biopsy for lung cancer is launched by Delfi

PeterBach,shownatthe2019STATsummit,isnowchiefmedicalofficerofDelfi.EmiliePickeringforSTATDelfiDiagno

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

FDA drug safety: Singulair case shows systemic surveillance flaws

AdobeAfteradrugentersthemarket,it’suptoFoodandDrugAdministrationregulatorstoensureitscontinuedsafety